



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

SEP 04 2001

RECEIVED

10

Applicants: Gosselin et al.

Serial No.: 09/371,747

Group Art Unit: 1623

Filed: August 8, 1999

Examiner: L. Eric Crane

For: β-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B

Assistant Commissioner for Patents
Washington, DC 20231

August 27, 2001

Terminal Disclaimer

Sir:

Assignees, Novirio Pharmaceuticals Limited and Centre National de la Recherche Scientifique, the owners of entire interest of U.S. Serial Nos. 09/371,747 and 09/459,150, through the undersigned attorney of record, hereby disclaim the terminal part of any patent granted on U.S. Serial No. 09/371,747 or 09/459,150 that would extend beyond the expiration date of the full statutory term of the other. Any patent granted on U.S. Serial No. 09/371,747 or 09/459,150 shall be enforceable only for and during such period that legal title to one of the patents shall be the same as legal title to the other and will be binding upon the grantee, its successors or assigns.

Gilles Gosselin and Jean-Louis Imbach have assigned U.S. Serial Nos. 09/371,747 and 09/459,150 to the Centre National de la Reserche Scientifique, while Martin Bryant has assigned U.S. Serial Nos. 09/371,747 and 09/459,150 to Novirio Pharmaceuticals Limited, whose addresses are of record, in an Assignment recorded on September 27, 1999, commencing at Reel 010271, Frame 0725.

Assignees do not disclaim any terminal part of any patent granted on U.S. Serial No. 09/371,747 or 09/459,150 prior to the expiration date of the full statutory term to the other of U.S. Serial No. 09/371,747 or 09/459,150 in the event that such patent later: a) expires for failure to pay a maintenance fee, b) is held unenforceable, c) is found invalid, d) is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), e) has all claims canceled by a reexamination certificate, or f) is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title stated above.

Please charge the \$110.00 fee for filing this Terminal Disclaimer, as well as any other fees required, to Deposit Account No. 11-0980.

Respectfully submitted,



Sherry M. Knowles
Reg. No. 33, 052

KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-3541 (Direct Line)
404-572-5145 (Facsimile)